Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. The company's mission is to provide innovative solutions for people fighting cardiovascular disease, driven by a passion to improve patient lives.

Edwards Lifesciences' key product areas include transcatheter heart valves, such as the Sapien transcatheter aortic heart valve, surgical valve technologies, and transcatheter mitral and tricuspid therapies. Additionally, the company develops critical care technologies, including advanced hemodynamic monitoring systems and pressure transducers. These products primarily serve the structural heart disease and critical care market segments.

Bernard J. Zovighian serves as the Chief Executive Officer, appointed in May 2023. As of May 2, 2026, Edwards Lifesciences announced 10-year results from its COMMENCE aortic trial, which demonstrated the long-term durability and sustained performance of its proprietary RESILIA tissue. The company reported strong first-quarter 2026 results, exceeding revenue and EPS expectations, and subsequently raised its full-year 2026 guidance. Edwards Lifesciences maintains a leading position as a global structural heart innovation company, particularly dominating the Transcatheter Aortic Valve Replacement (TAVR) market, with an estimated 60-70% U.S. market share as of 2025, and is expanding its presence in Transcatheter Mitral and Tricuspid Therapies (TMTT).